pre-IPO PHARMA

COMPANY OVERVIEW

Cessation Therapeutics is an early-stage pharmaceutical company working to develop novel immunobiologics designed to prevent and protect against overdose. With an initial focus on fentanyl, Cessation’s monoclonal antibodies can be adapted to target future synthetic opioids and other substances. Cessation has the potential to treat a range of substance use disorders and improve the lives of patients and families affected by the addiction crisis.


LOCATION


THERAPEUTIC AREAS


WEBSITE

https://www.cessationtherapeutics.com


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Jul 27, 2023

Cessation Therapeutics Announces Food and Drug Administration Authorization for First-in-Human Clinical Trial of Antibody for Prevention of Fentanyl Overdose


Feb 28, 2023

Cessation Therapeutics’ Anti-Fentanyl Monoclonal Antibody Treatment Shows Promise in Protecting Against Fentanyl-Induced Overdose


May 2, 2014

Research and Markets: Smoking Cessation Therapeutics Pipeline Review 2014 - Detailing 16 Companies and 25 Drug Profiles


For More Press Releases


Google Analytics Alternative